605 related articles for article (PubMed ID: 14581436)
21. Effect of intravesical treatment of transitional cell carcinoma with bacillus Calmette-Guerin and mitomycin C on urinary survivin levels and outcome.
Hausladen DA; Wheeler MA; Altieri DC; Colberg JW; Weiss RM
J Urol; 2003 Jul; 170(1):230-4. PubMed ID: 12796695
[TBL] [Abstract][Full Text] [Related]
22. Holmium laser treatment for low grade, low stage, noninvasive bladder cancer with local anesthesia and early instillation of mitomycin C.
Soler-Martínez J; Vozmediano-Chicharro R; Morales-Jiménez P; Hernández-Alcaraz D; Vivas-Vargas E; Santos García-Vaquero I; Baena-González V
J Urol; 2007 Dec; 178(6):2337-9. PubMed ID: 17936805
[TBL] [Abstract][Full Text] [Related]
23. A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus mitomycin C.
Ojea A; Nogueira JL; Solsona E; Flores N; Gómez JM; Molina JR; Chantada V; Camacho JE; Piñeiro LM; Rodríguez RH; Isorna S; Blas M; Martínez-Piñeiro JA; Madero R;
Eur Urol; 2007 Nov; 52(5):1398-406. PubMed ID: 17485161
[TBL] [Abstract][Full Text] [Related]
24. Intravesical mitomycin C for superficial transitional cell carcinoma.
Bolenz C; Cao Y; Arancibia MF; Trojan L; Alken P; Michel MS
Expert Rev Anticancer Ther; 2006 Aug; 6(8):1273-82. PubMed ID: 16925493
[TBL] [Abstract][Full Text] [Related]
25. Maintenance therapy for superficial bladder cancer.
Baselli EC; Greenberg RE
Oncology (Williston Park); 2001 Jan; 15(1):85-8; discussion 88-91. PubMed ID: 11271984
[TBL] [Abstract][Full Text] [Related]
26. Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression.
Böhle A; Bock PR
Urology; 2004 Apr; 63(4):682-6; discussion 686-7. PubMed ID: 15072879
[TBL] [Abstract][Full Text] [Related]
27. Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder carcinoma.
Friedrich MG; Pichlmeier U; Schwaibold H; Conrad S; Huland H
Eur Urol; 2007 Oct; 52(4):1123-29. PubMed ID: 17383080
[TBL] [Abstract][Full Text] [Related]
28. Effect of local hyperthermia of the bladder on mitomycin C pharmacokinetics during intravesical chemotherapy for the treatment of superficial transitional cell carcinoma.
Paroni R; Salonia A; Lev A; Da Pozzo LF; Cighetti G; Montorsi F; Rigatti P; Colombo R
Br J Clin Pharmacol; 2001 Sep; 52(3):273-8. PubMed ID: 11560559
[TBL] [Abstract][Full Text] [Related]
29. [Intravesical instillation in the treatment of superficial tumors of the bladder].
Chopin DK
Prog Urol; 1998 Apr; 8(2):268-73. PubMed ID: 9615941
[TBL] [Abstract][Full Text] [Related]
30. Long-term outcomes of a randomized controlled trial comparing thermochemotherapy with mitomycin-C alone as adjuvant treatment for non-muscle-invasive bladder cancer (NMIBC).
Colombo R; Salonia A; Leib Z; Pavone-Macaluso M; Engelstein D
BJU Int; 2011 Mar; 107(6):912-8. PubMed ID: 21029314
[TBL] [Abstract][Full Text] [Related]
31. [Long-term results of intravesical N-CWS instillation to prevent recurrence after surgery for bladder cancer].
Chen S; Lin Z; Xu E
Zhonghua Zhong Liu Za Zhi; 1997 May; 19(3):228-30. PubMed ID: 10920905
[TBL] [Abstract][Full Text] [Related]
32. Intravesical chemotherapy for maximum prophylaxis of new early phase superficial bladder carcinoma treated by transurethral resection: a combined analysis of trials by the Japanese Urological Cancer Research Group using smoothed hazard function.
Hinotsu S; Akaza H; Ohashi Y; Kotake T
Cancer; 1999 Nov; 86(9):1818-26. PubMed ID: 10547556
[TBL] [Abstract][Full Text] [Related]
33. Analysis of progression and survival after 10 years of a randomized prospective study comparing mitomycin-C and bacillus Calmette-Guérin in patients with high-risk bladder cancer.
Gårdmark T; Jahnson S; Wahlquist R; Wijkström H; Malmström PU
BJU Int; 2007 Apr; 99(4):817-20. PubMed ID: 17244282
[TBL] [Abstract][Full Text] [Related]
34. Twelve-year follow up of a randomized prospective trial comparing bacillus Calmette-Guerin and epirubicin as adjuvant therapy in superficial bladder cancer.
Cheng CW; Chan SF; Chan LW; Chan CK; Ng CF; Cheung HY; Chan SY; Wong WS; Lai FM; To KF; Li ML
Int J Urol; 2005 May; 12(5):449-55. PubMed ID: 15948743
[TBL] [Abstract][Full Text] [Related]
35. Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term followup.
Solsona E; Iborra I; Ricós JV; Monrós JL; Casanova J; Dumont R
J Urol; 1999 Apr; 161(4):1120-3. PubMed ID: 10081851
[TBL] [Abstract][Full Text] [Related]
36. Intravesical epirubicin versus doxorubicin for superficial bladder tumors (stages pTa and pT1): a randomized prospective study.
Ali-el-Dein B; el-Baz M; Aly AN; Shamaa S; Ashamallah A
J Urol; 1997 Jul; 158(1):68-73; discussion 73-4. PubMed ID: 9186325
[TBL] [Abstract][Full Text] [Related]
37. [Long-term results of intravesical prevention of recurrence with mitomycin C and adriamycin in patients with superficial bladder cancer].
Schwaibold H; Klingenberger HJ; Huland H
Urologe A; 1994 Nov; 33(6):479-83. PubMed ID: 7817443
[TBL] [Abstract][Full Text] [Related]
38. Comparison of three schedules of intravesical epirubicin in patients with non-muscle-invasive bladder cancer.
Hendricksen K; Witjes WP; Idema JG; Kums JJ; van Vierssen Trip OB; de Bruin MJ; Vergunst H; Caris CT; Janzing-Pastors MH; Witjes JA
Eur Urol; 2008 May; 53(5):984-91. PubMed ID: 18248876
[TBL] [Abstract][Full Text] [Related]
39. Should all patients with non-muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? The results of a prospective randomised multicentre study.
Gudjónsson S; Adell L; Merdasa F; Olsson R; Larsson B; Davidsson T; Richthoff J; Hagberg G; Grabe M; Bendahl PO; Månsson W; Liedberg F
Eur Urol; 2009 Apr; 55(4):773-80. PubMed ID: 19153001
[TBL] [Abstract][Full Text] [Related]
40. Increasing patient comfort by optimized postoperative administration of intravesical mitomycin C.
Stoehr B; Mueller T; Granig T; Zangerl F; Steiner H
BJU Int; 2008 Dec; 102(11):1556-9. PubMed ID: 18691179
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
